Internal Medicine, Hematology & Oncology · Aurora, CO
NPI
1801915822
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
12605 E 16th Ave
Aurora, CO, 80045
Phone (720) 777-1234
Groups this clinician bills Medicare through
Medicare paid, 2024
$36K
381 services
Medicare patients, 2024
102
Average age 75
Drug cost, 2024
$2.6M
445 prescriptions
Company payments, 2025
$31K
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Daniel A Pollyea was code 99233 (hospital e&m - subsequent), 218 times for 49 patients. In total Daniel A Pollyea billed 381 services in 5 codes, and Medicare paid $36K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-06-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 218 | 49 | $93.16 | $20K |
| 99215 Office E&M - Established | Facility | 89 | 42 | $109.75 | $9,767 |
| 99214 Office E&M - Established | Facility | 37 | 23 | $66.58 | $2,463 |
By year: 2022 $35K for 442 services; 2023 $37K for 408 services; 2024 $36K for 381 services.
Medicare prescription drug claims, 2024
In 2024, the drug Daniel A Pollyea prescribed most often to Medicare patients was Acyclovir, with 49 prescriptions and refills. In total Daniel A Pollyea wrote 445 Medicare prescriptions that cost $2.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Acyclovir Generic | 49 | 82 | 16 | $881 |
| Venclexta Venetoclax | 42 | 42 | 13 | $618K |
| Tasigna Nilotinib Hcl | 40 | 40 | Under 11 | $487K |
| Sprycel Dasatinib | 28 | 28 | Under 11 | $126K |
| Tibsovo Ivosidenib | 27 | 27 | Under 11 | $792K |
| Ondansetron Hcl Generic | 22 | 24 | Under 11 | $189 |
| Imatinib Mesylate Generic | 21 | 21 | Under 11 | $31K |
| Inqovi Decitabine/Cedazuridine | 20 | 20 | Under 11 | $160K |
| Levofloxacin Generic | 17 | 27 | 12 | $329 |
| Fluconazole Generic | 16 | 24 | Under 11 | $798 |
| Granisetron Hcl Generic | 14 | 24 | Under 11 | $2,755 |
| Prochlorperazine Maleate Generic | 14 | 14 | Under 11 | $132 |
| Imbruvica Ibrutinib | 12 | 12 | Under 11 | $70K |
| Potassium Chloride Generic | 11 | 11 | Under 11 | $60.75 |
| Celecoxib Generic | 11 | 11 | Under 11 | $199 |
Brand drugs: 205 claims; generic drugs: 240 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Daniel A Pollyea $31K ($31K in general payments such as food, travel and fees) from 16 companies. The largest payer was Servier Pharmaceuticals LLC with $6,054.
| Company | Payments | Amount |
|---|---|---|
| Servier Pharmaceuticals LLC | 8 | $6,054 |
| Abbvie Inc. ABBV | 9 | $4,993 |
| Geron Corporation GERN | 6 | $4,224 |
| Syndax Pharmaceuticals, Inc. SNDX | 5 | $3,777 |
| E.R. Squibb & Sons, L.L.C. BMY | 1 | $2,865 |
| Astellas Pharma US Inc 4503.T | 2 | $2,722 |
| Astellas Pharma Global Development 4503.T | 1 | $2,652 |
| Genentech USA, Inc. ROG.SW | 2 | $1,847 |
| Genmab U.S., Inc. GMAB | 1 | $785 |
| Rigel Pharmaceuticals, Inc. RIGL | 1 | $685 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.